{"name":"Vivos Therapeutics","slug":"vivos","ticker":"VVOS","exchange":"NASDAQ","domain":"vivoslife.com","description":"Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.","hq":"Littleton, CO","founded":0,"employees":"262","ceo":"Kirk Huntsman","sector":"Dental / Sleep Medicine","stockPrice":1.23,"stockChange":-0.01,"stockChangePercent":-0.81,"marketCap":"$14M","metrics":{"revenue":15031000,"revenueGrowth":75.7,"grossMargin":55.7,"rdSpend":100000,"netIncome":-11136000,"cash":3087000,"dividendYield":0,"peRatio":-1,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Vivos Therapeutics reported revenue of $10.2 million for the fourth quarter of 2023, a 25% increase from the same period in 2022.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Vivos Therapeutics Announces Partnership with Dental Sleep Medicine Provider","summary":"Vivos Therapeutics has partnered with a leading dental sleep medicine provider to expand its reach and improve patient access to its products.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxOUldiUjFkQ0JsS1hLQWxDdnhBUm9SYUpjQjFxeGZ3XzBYeFlCN3NRU2dmOFBDcnBZOUx0UzlDak8wX1hvTXdYWHlTNFM4dVdQUDFPOTJsY3lPUm5pWWV5R25LVEVoZHg5SUhxRFk4MlJfeTg5eW9FMjVVUDliaG53cGdnX1AwMzZLWl9YUXd5SHRQYzJOUkc5bmJyRm5yWFA2NXR5ZGVnNzRaZ2xsUzVQUGVwUUdISm9DdTBnTFFNeldOcnI1ZG1XTGhUeXMydzdwOGpDZm5FV29HSXUxYVp6dXVWeE1nRThEaUdCd3V4TFJpRG9MaWE5SmtZVWRSNi1oTk44RGZDOTBSN0ZweVY3dVRtV3JSSk5RUVpsSldWaGRHQW4zZzNlMkZHN0tRUmZhUHlfU0E0OTc?oc=5","date":"2026-02-28","type":"pipeline","source":"norfolkdailynews.com","summary":"New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (NYSE:CITR), Vivos Therapeutics, Inc. (NASDAQ:VVOS), and Virtuix Holdings ($VTIX) ","headline":"New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (N","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxNaUd6NFh4NHVQa2hHazBwbGNiYVM4cVdPMGduR29meTRUYVZ6a0xJUW1hUU12T3BYSlZ0UnpobFNKSTkzTzlLMDZ2SFRtVTVJOEE1dDBoTmlrSGhLbEdJcEUwT3V0MlVMVmtqY0VCWDdnclRQdVA1M01lbjJSeFJQM3hnUkRNTmZ4N25QcWFyWGlXSmc0M1JHM2lpVmt6NGNzS29lZUQ4U2x5Skxobm0zelJ2dHJpMjNSVGVSbEtPc2hZRFAyS05aU2Vub2otUjNuN2YwR1FMck1aZ2l0YW9IRHg0amhadXdkUTdkYW15RDdHeWVuZE93TndIemw4dENsbFhhbWJ0bWlZbUpLaWJ0bEZJT0M3OXlmQTZNM09zUVpDb05sM0ZPX2lRSmQ?oc=5","date":"2026-02-28","type":"pipeline","source":"kdhnews.com","summary":"New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (NYSE:CITR), Vivos Therapeutics, Inc. (NASDAQ:VVOS), and Virtuix Holdings ($VTIX) ","headline":"New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (N","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-19","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOaWR4MVRrMkUzQVhZQnpWVmhtdWxlVUFPMmlHVlFrZVJrLXFpNE5iMDNKeVF5eFBBdmNmeExVUGZ3M0d2dVhzY3d2cWhZQVdsQTVmQUhLeGVXeWxvQkV1ZGxudE9aQXBrQWY4Um5mNW9JbXVVS2lEbFdMUEVJQ01TaDJYODVUMFlL?oc=5","date":"2024-04-09","type":"pipeline","source":"InvestorPlace","summary":"Why Is Laser Photonics (LASE) Stock Up 130% Today? - InvestorPlace","headline":"Why Is Laser Photonics (LASE) Stock Up 130% Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTFB3V1JGU0p4QlduaHdhcVhJTXpUd25nMTdaeDIzZTFRa291ejZfbWxoWmpXQlJ4YjZ6ZldOT3RseFlxYzBRaGVBYU1uRkpZVHltQmQtZVQ2UW9MdnFwYjlKZDhlMVJOVDQ?oc=5","date":"2020-10-12","type":"pipeline","source":"Benzinga","summary":"Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga","headline":"Best Biotech Penny Stocks Right Now • Updated Daily","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["RespireRx Pharmaceuticals","Inspire Medical Systems","Somnium Therapeutics"],"therapeuticFocus":["Sleep-Disordered Breathing","Obstructive Sleep Apnea"],"financials":{"source":"sec_edgar","revenue":15031000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":15031000,"period":"2024-12-31"},{"value":13801000,"period":"2023-12-31"},{"value":13801000,"period":"2023-12-31"},{"value":16024000,"period":"2022-12-31"},{"value":16024000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":100000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-11136000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":15284000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.23,"previousClose":1.24,"fiftyTwoWeekHigh":7.95,"fiftyTwoWeekLow":1.08,"fiftyTwoWeekRange":"1.085 - 7.95","fiftyDayAverage":1.44,"twoHundredDayAverage":2.87,"beta":6.9,"enterpriseValue":21185418,"forwardPE":-1,"priceToBook":4,"priceToSales":0.84,"enterpriseToRevenue":1.22,"enterpriseToEbitda":-1.38,"pegRatio":0,"ebitda":-15307000,"ebitdaMargin":-88.4,"freeCashflow":-9380750,"operatingCashflow":-14391000,"totalDebt":12498000,"debtToEquity":493.6,"currentRatio":0.78,"returnOnAssets":-49.8,"returnOnEquity":-335.5,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":3,"targetMeanPrice":5,"targetHighPrice":7,"targetLowPrice":2.5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":20.5,"institutionHeldPercent":9.6,"sharesOutstanding":11821413,"floatShares":5333452,"sharesShort":484373,"shortRatio":5.83,"shortPercentOfFloat":4.6,"epsTrailing":-1.66,"epsForward":-1.25,"revenuePerShare":1.93,"bookValue":0.31,"officers":[{"age":67,"name":"Mr. R. Kirk Huntsman","title":"Co-Founder, Chairman of the Board & CEO"},{"age":63,"name":"Mr. Bradford K. Amman","title":"CFO, Treasurer & Secretary"},{"age":null,"name":"Mr. Todd  Huntsman","title":"Co-Founder & Senior VP of Product and Technology"},{"age":null,"name":"Ms. RaeAnn  Byrnes","title":"Co-Founder and Senior VP of Events & Clinical Advisory Services"},{"age":null,"name":"Ms. Susan  McCullough","title":"Co-Founder & Executive VP of Operations"},{"age":null,"name":"Dr. Terry  Jones","title":"Senior VP of Human Resources"},{"age":null,"name":"Mr. Nicholas M. DeGennaro","title":"Senior Vice President of Mergers and Acquisition Group"},{"age":null,"name":"Ms. Ruth  Hembree","title":"Senior Vice President of Practice Services"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.vivos.com","phone":"844 672 4357"}}